CLLS - Cellectis SA logo

Cellectis SA

CLLS

Cellectis SA develops gene-editing technologies for immuno-oncology, focusing on allogeneic chimeric antigen receptor T-cell therapies for various cancers, including acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

โš•๏ธ Healthcare NASDAQ Listed 2007 $ USD
$1,000 invested 10 years ago โ†’$58today

Score Overview

1 Year
Score
Net Growth3.28%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-22.42%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.8
Net Growth24.23%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-23.47%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-2.28%
Net Trend40%
Net Income Consistency
Rev Growth32.90%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-13x
Net Trend35%
Net Income Consistency
Rev Growth13x
Rev Trend53%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Cellectis SA has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. CLLS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-01
$ 1.40โ€”
1 Year2025-10-01
$ 3.29-57.45%
5 Years2021-10-01
$ 12.69-88.97%
10 Years2016-09-30
$ 24.08-94.19%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 56M-$ 65M$ 166M
2025$ 72M-$ 67M$ 208M
2024$ 41M-$ 36M$ 260M
2023$ 755K-$ 101M$ 203M
2022$ 19M-$ 98M$ 97M
2021$ 73M-$ 86M$ 186M
2020$ 73M-$ 72M$ 268M
2019$ 15M-$ 90M$ 360M
2018$ 12M-$ 78M$ 451M
2017$ 25M-$ 99M$ 296M
2016$ 42M-$ 63M$ 290M
2015$ 55M-$ 22M$ 343M
2014$ 26M$ 136M
2013$ 22M-$ 84M$ 10M
2012$ 27M-$ 29M$ 28M
2011$ 20M-$ 30M$ 54M
2010$ 20M-$ 10M$ 31M
2009$ 17M-$ 5M$ 65M
2008$ 14M$ 185.15K$ 39M
IPO2007$ 4M-$ 4M$ 36M
CLLS - Cellectis SA logo

Cellectis SA fundamental performance

Between 2020 and 2025, revenue declined from $ 73M to $ 72M and net income went from -$ 72M to -$ 67M. Revenue increased in 2 of those 5 years; net income in 2.

Across Cellectis SA's full reported history, from 2007 to 2025, revenue grew from $ 4M to $ 72M and net income went from -$ 4M to -$ 67M. Revenue increased in 53% of the years measured; net income in 35%.

Cellectis SA currently holds a 5-year HDB Score of 3.8 out of 10. How the HDB Score is calculated.

Membership

Explore CLLS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies